Log in

Relevant bibliographies by topics / Cancer du sein basal-Like / Journal articles

To see the other types of publications on this topic, follow the link: Cancer du sein basal-Like.

Journal articles on the topic 'Cancer du sein basal-Like'

Author: Grafiati

Published: 30 November 2024

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Cancer du sein basal-Like.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Treilleux, Isabelle, and Blandine Morellon-Mialhe. "Le cancer du sein de phénotype basal." Annales de Pathologie 29, no. 3 (2009): 180–86. http://dx.doi.org/10.1016/j.annpat.2009.04.001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Garcia de la Fuente, I., F. Jolicoeur, A. Robidoux, I. Gorska, D. Balicki, and L. Gaboury. "Caractérisation du cancer du sein de phénotype basal." Annales de Pathologie 26, no. 1 (2006): 69–70. http://dx.doi.org/10.1016/s0242-6498(06)70671-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Vincent-Salomon, A., G. Macgrogan, E. Charaffe-Jauffret, J. Jacquemier, and L. Arnould. "Identification en pratique clinique des carcinomes basal-like du sein : des carcinomes « triple zéro/BRCA1-like »." Bulletin du Cancer 97, no. 3 (2010): 357–63. http://dx.doi.org/10.1684/bdc.2010.1062.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Leidy, Jennifer, Ashraf Khan, and Dina Kandil. "Basal-Like Breast Cancer: Update on Clinicopathologic, Immunohistochemical, and Molecular Features." Archives of Pathology & Laboratory Medicine 138, no. 1 (2014): 37–43. http://dx.doi.org/10.5858/arpa.2012-0439-ra.

Full text

Abstract:

Context.—Basal-like breast carcinoma (BLBC) is a distinct molecular subtype of breast carcinoma identified through gene expression profiling studies. Objective.—To provide the clinical background, the histologic profile, and the immunohistochemical profile of these tumors and discuss the current knowledge of their molecular signature and their implications on targeted molecular therapy. Data Sources.—Data were obtained from review of the pertinent peer-reviewed literature. Conclusions.—Basal-like breast carcinomas are aggressive tumors with poor prognosis. Lack of targeted therapy makes their

APA, Harvard, Vancouver, ISO, and other styles

5

Liu, Ming, Julia Y. S. Tsang, Michelle Lee, et al. "CD147 expression is associated with poor overall survival in chemotherapy treated triple-negative breast cancer." Journal of Clinical Pathology 71, no. 11 (2018): 1007–14. http://dx.doi.org/10.1136/jclinpath-2018-205342.

Full text

Abstract:

AimsIn breast cancer models, the functional roles of CD147 in proliferation, invasion and treatment resistance have been widely reported. However, there are only a few studies examining the clinicopathological correlation and prognostic relevance of CD147 in breast cancer, especially in relation to breast cancer molecular subtypes.MethodsIn this study, we analysed CD147 expression in a large cohort of breast cancers, correlating with clinicopathological features and the expression of a comprehensive panel of biomarkers in triple-negative breast cancer (TNBC) and non-TNBC subsets. Its relations

APA, Harvard, Vancouver, ISO, and other styles

6

Kardos, Jordan, Jonathan J. Melquist, David D. Chism, et al. "Evaluation of basal and luminal subtypes of urothelial carcinoma in African American and non-African American patients." Journal of Clinical Oncology 33, no. 7_suppl (2015): 305. http://dx.doi.org/10.1200/jco.2015.33.7_suppl.305.

Full text

Abstract:

305 Background: African American (AA) patients with urothelial carcinoma (UC) have been known to have a worse prognosis even when corrected for variables such as tumor stage and grade. Analysis of gene expression of several malignancies has resulted in the discovery of molecular subtypes with well-defined intrinsic biology. Recent studies in high grade (HG), muscle-invasive UC have led to the identification of two intrinsic, molecular subsets termed “luminal” and “basal” with characteristics of stages of urothelial differentiation, and that remarkably reflect the luminal and basal-like molecul

APA, Harvard, Vancouver, ISO, and other styles

7

Mayer, Ingrid A., Rebecca Dent, Tira Tan, Peter Savas, and Sherene Loi. "Novel Targeted Agents and Immunotherapy in Breast Cancer." American Society of Clinical Oncology Educational Book, no. 37 (May 2017): 65–75. http://dx.doi.org/10.1200/edbk_175631.

Full text

Abstract:

The treatment of breast cancer is generally determined according to breast cancer subtype: hormone receptor–positive (luminal), triple-negative (basal-like), and HER2-overexpressing breast cancer. Recent years have seen the development of exciting novel and potent therapeutics based on molecular pathways, immune modulation, and antibody conjugates. In this article, we cover new and emerging therapeutic areas and ongoing clinical trials that may result in further improvements in breast cancer outcomes.

APA, Harvard, Vancouver, ISO, and other styles

8

Chukwuma, Uzoigwe J., Nzegwu M. Arinze, Onyishi N. Thaddeus, et al. "The Histological Subtypes of Breast Cancer Seen in a Tertiary Hospital in South-East, Nigeria." Global Journal of Health Science 12, no. 6 (2020): 93. http://dx.doi.org/10.5539/gjhs.v12n6p93.

Full text

Abstract:

INTRODUCTION: Breast cancer is a disease with heterogeneous nature that may have different prognosis and respond to therapy differently despite similarities in histological type, grade and stage. It is common among women in both developed and developing countries of the world.&nbsp;  MATERIALS AND METHODS: This study was a 2-year retrospective study involving a systematic analysis of all the formalin-fixed paraffin-embedded tissue blocks previously diagnosed as breast cancers. The study occurred at the Department of Morbid Anatomy, University of Nigeria Teaching Hospital, Enugu

APA, Harvard, Vancouver, ISO, and other styles

9

Gao, Yang, Elena B. Kabotyanski, Jonathan H. Shepherd, et al. "Tumor Suppressor PLK2 May Serve as a Biomarker in Triple-Negative Breast Cancer for Improved Response to PLK1 Therapeutics." Cancer Research Communications 1, no. 3 (2021): 178–93. http://dx.doi.org/10.1158/2767-9764.crc-21-0106.

Full text

Abstract:

Polo-like kinase (PLK) family members play important roles in cell-cycle regulation. The founding member PLK1 is oncogenic and preclinically validated as a cancer therapeutic target. Paradoxically, frequent loss of chromosome 5q11–35, which includes PLK2, is observed in basal-like breast cancer. In this study, we found that PLK2 was tumor suppressive in breast cancer, preferentially in basal-like and triple-negative breast cancer (TNBC) subtypes. Knockdown of PLK1 rescued phenotypes induced by PLK2 loss both in vitro and in vivo. We also demonstrated that PLK2 directly interacted with PLK1 at

APA, Harvard, Vancouver, ISO, and other styles

10

Ladewig, Erik, Abbas Nazir, Christina Leslie, and Charles Sawyers. "Abstract 2048: Mutations in FOXA1 alter chromatin remodeling and cell fate in prostate organoids." Cancer Research 83, no. 7_Supplement (2023): 2048. http://dx.doi.org/10.1158/1538-7445.am2023-2048.

Full text

Abstract:

Abstract Genomic analysis of targeted patient tumor sequencing identified frequent mutations, 41% in prostate cancer (Li, et al., 2020) in the gene FOXA1, a developmentally important pioneer transcription factor (TF) in mammary and prostate tissues. Previous work by our group and others has shown that these FOXA1 mutations alter global chromatin accessibility and promote growth in prostate cells (Adams, 2019), but the underlying molecular details, including the identity of partner TFs, remain unclear. To address this topic, we generated mouse prostate organoids expressing Foxa1 alleles harbori

APA, Harvard, Vancouver, ISO, and other styles

11

Jomaa, W., S. Ziadi, R. Ben Gacem, et al. "Le cancer du sein de phénotype basal : prévalence et particularités anatomo-cliniques dans la région du centre tunisien." Annales de Pathologie 31, no. 5 (2011): S162. http://dx.doi.org/10.1016/j.annpat.2011.09.095.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Araujo, Jhajaira M., Gabriel De la Cruz-Ku, Melanie Cornejo, et al. "Prognostic Capability of TNBC 3-Gene Score among Triple-Negative Breast Cancer Subtypes." Cancers 14, no. 17 (2022): 4286. http://dx.doi.org/10.3390/cancers14174286.

Full text

Abstract:

Background: Triple-negative breast cancer (TNBC) is a complex and molecularly heterogeneous entity, with the poorest outcome compared with other breast cancer subtypes. Previously, we developed a TNBC 3-gene score with a significant prognostic capability. This study aims to test the 3-gene score in the different TNBC subtypes. Methods: Data from 204 TNBC patients treated with neoadjuvant chemotherapy were retrieved from public datasets and pooled (GSE25066, GSE58812, and GSE16446). After removing batch effects, cases were classified into Lehman’s TNBC subtypes and then the TNBC 3-gene score wa

APA, Harvard, Vancouver, ISO, and other styles

13

Hamada, Akihiro, Yuki Kita, Di Wu, et al. "Abstract A016: NRF2 activation promotes a fitness disadvantage in normal urothelium and drives a basal-like phenotype." Clinical Cancer Research 30, no. 10_Supplement (2024): A016. http://dx.doi.org/10.1158/1557-3265.bladder24-a016.

Full text

Abstract:

Abstract Introduction: Nuclear factor erythroid 2-related factor 2 (NRF2) is a transcription factor that plays a key role in protecting cells from oxidative stress. NRF2 is negatively controlled by Kelch-like ECH-associated protein 1 (KEAP1), which facilitates NRF2 ubiquitination and proteosomal degradation under homeostatic conditions. NRF2 activating mutations occur at a frequency of 5.9% in muscle-invasive bladder cancer (MIBC). However, the role of NRF2 in MIBC has not been fully understood. The aim of this study is to clarify how NRF2 affect to the normal epithelial cells and the tumor ce

APA, Harvard, Vancouver, ISO, and other styles

14

O'Kane, Grainne M., Sandra Fischer, Rob Denroche, et al. "Integrative molecular profiling and response to chemotherapy on the COMPASS trial." Journal of Clinical Oncology 37, no. 4_suppl (2019): 188. http://dx.doi.org/10.1200/jco.2019.37.4_suppl.188.

Full text

Abstract:

188 Background: Predictive mutational and transcriptional features in advanced PDAC are needed for improved patient stratification and treatment selection. Methods: Patients (pts) on the COMPASS trial with advanced PDAC are prospectively recruited prior to first-line chemotherapy for WGS and RNAseq. Tumor tissue undergoes enrichment by laser capture microdissection with genomic analyses available within eight wks. Tumor responses and clinical outcomes in this maturing cohort were correlated with molecular characteristics. Results: 157 pts underwent a tumor biopsy between Dec 2015 and Jul 2018

APA, Harvard, Vancouver, ISO, and other styles

15

Van Swearingen, Amanda, Marissa Lee, Layne Rogers, et al. "Abstract PO4-14-07: Genomic and immune profiling of breast cancer brain metastases." Cancer Research 84, no. 9_Supplement (2024): PO4–14–07—PO4–14–07. http://dx.doi.org/10.1158/1538-7445.sabcs23-po4-14-07.

Full text

Abstract:

Abstract BACKGROUND: Brain metastases (BrM) arising from breast cancer (BC) are an increasing consequence of advanced disease, with up to half of patients (pts) with metastatic HER2+ or triple negative breast cancer experiencing central nervous system (CNS) recurrence. The genomic alterations driving CNS recurrence, along with contribution of the immune microenvironment, particularly by BC subtype remains unclear. METHODS: We characterized BrM from a cohort of n=42 BC pts by sequencing whole-exome DNA and total RNA libraries from frozen (n=31) and FFPE (n=34) BCBrM, FFPE extracranial (ECT, n=1

APA, Harvard, Vancouver, ISO, and other styles

16

Sangera-Grewal, Ravina, and Parbeer Singh Grewal. "Gorlin Syndrome Presentation and the Importance of Differential Diagnosis of Skin Cancer: A Case Report." Journal of Pharmacy & Pharmaceutical Sciences 21, no. 1s (2018): 222s—224s. http://dx.doi.org/10.18433/jpps30150.

Full text

Abstract:

In a busy community practice, clinical skin findings can often be misinterpreted. Skin cancers can sometimes mimic rashes like psoriasis, eczema or prurigo nodularis in both appearance and symptoms. Gorlin syndrome is one such genetic syndrome, characterized by the eruption of multiple and early onset basal cell carcinomas (BCCs), which can be mistaken for a rash. We describe a 68-year-old female who presented to the dermatology office with a previous history of over 30 BCCs that had been previously biopsied and/or surgically removed. However, the patient had been lost to follow up for several

APA, Harvard, Vancouver, ISO, and other styles

17

Foldi, Julia, Emily Reisenbichler, Liuliu Pan, Krsitina Sorg, Sarah E. Church, and Lajos Pusztai. "Abstract P1-05-02: Intratumor molecular tumor heterogeneity in low ER-expressing primary breast tumors." Cancer Research 82, no. 4_Supplement (2022): P1–05–02—P1–05–02. http://dx.doi.org/10.1158/1538-7445.sabcs21-p1-05-02.

Full text

Abstract:

Abstract Background: Change in estrogen receptor (ER) status between primary breast cancer and distant recurrence are seen in the clinic in up to 15-20% of patients. This is difficult to reconcile with the current understanding of breast cancer molecular subtypes, the large-scale molecular differences between ER-positive (ER+) and ER-negative (ER-) cancers suggest different cellular origins, luminal versus basal breast epithelium, respectively. A potential explanation for ER status switch is the presence of mixed molecular subtypes at diagnosis. ER+ cancers with less than 100% positivity may b

APA, Harvard, Vancouver, ISO, and other styles

18

Ivory, Joannie M., Naim Rashid, Paola Zagami, Charles M. Perou, Katherine Elizabeth Reeder-Hayes, and Lisa A. Carey. "Impact of race and age on intrinsic subtype distribution and treatment decisions in metastatic breast cancer: Preliminary analysis of HARMONY (LCCC1829)." Journal of Clinical Oncology 41, no. 16_suppl (2023): 1055. http://dx.doi.org/10.1200/jco.2023.41.16_suppl.1055.

Full text

Abstract:

1055 Background: Gene expression profiling (GEP) is used to classify breast cancer (BC) into four intrinsic subtypes: Luminal A (LumA), Luminal B (LumB), HER2-Enriched, and Basal-like. Non-LumA subtypes are associated with poorer outcomes. Studies in early BC show that hormone receptor-positive (HR+)/HER2-negative (HER2-) tumors have a higher frequency of non-LumA subtypes in Black and younger (<50) women. Similarly, triple negative BC, which carries the poorest prognosis and is mostly Basal-like, are overrepresented in Black and younger women. These variations in intrinsic subtype contribu

APA, Harvard, Vancouver, ISO, and other styles

19

Emens, Leisha A., Leonard D. Goldstein, Peter Schmid, et al. "The tumor microenvironment (TME) and atezolizumab + nab-paclitaxel (A+nP) activity in metastatic triple-negative breast cancer (mTNBC): IMpassion130." Journal of Clinical Oncology 39, no. 15_suppl (2021): 1006. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.1006.

Full text

Abstract:

1006 Background: IMpassion130 was the first randomized phase 3 study to show clinical benefit of cancer immunotherapy (CIT) in untreated PD-L1+ mTNBC. Enhanced A + nP efficacy vs placebo (P) + nP was seen in pts with a richer immune TME but was confined to PD-L1 IC+ pts (PD-L1–expressing immune cells on ≥1% of tumor area; Emens JNCI 2021). While TNBC molecular subtyping and CD8 localization are prognostic in early TNBC, it is unknown whether these features are associated with CIT benefit in mTNBC. This exploratory analysis aimed to identify TME components associated with A + nP efficacy in IMp

APA, Harvard, Vancouver, ISO, and other styles

20

Bordonaro, Sebastiano, Massimiliano Berretta, Antonino Carmelo Tralongo, Silvia Clementi, Brigida Stanzione, and Paolo Tralongo. "The Real Impact of Target Therapy in Breast Cancer Patients: Between Hope and Reality." Current Cancer Drug Targets 18, no. 5 (2018): 480–98. http://dx.doi.org/10.2174/1568009617666170209100322.

Full text

Abstract:

Over the last 15 years, we have seen a huge expansion of the development of drugs directed against biomolecular targets within breast cancer cells. The over-expression of certain receptors (ER, PgR, HER-2, VEGF-R), as well as alteration of several intracellular signal transduction pathways (the PI3K-AKT-mTOR pathway, MEK-MAPK pathway, loss of PTEN, etc ...) has a great impact on the likelihood of recurrence and progression of the disease, influencing the natural history of breast cancer. The recent biomolecular classification of breast cancer (Luminal A / B, HER2- driven, Basal Like) allowed f

APA, Harvard, Vancouver, ISO, and other styles

21

Snider, Jessica N., Robyn R. Young, Lee Steven Schwartzberg, et al. "Neoadjuvant bevacizumab with weekly nab-paclitaxel plus carboplatin followed by doxorubicin plus cyclophosphamide (AC) for triple-negative breast cancer." Journal of Clinical Oncology 30, no. 15_suppl (2012): TPS1137. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.tps1137.

Full text

Abstract:

TPS1137 Background: Triple negative breast cancer (TNBC) predominantly clusters with “basal like” subtype on genomic profiling. Over-expression of Secreted Protein Acidic and Rich in Cysteine (SPARC) has been observed in basal like breast cancer (Charaffe-Jaufrett et al. Oncogene 2006; 2273-84). Endothelial transcytosis of nab- paclitaxel occurs via albumin- gp60 receptor-caveolin 1 interaction. SPARC entraps the albumin resulting in higher intratumoral accumulation, which may explain the increased efficacy of nab-paclitaxel (Desai et al. Translational Oncology 2009; 59-63). Exploiting this me

APA, Harvard, Vancouver, ISO, and other styles

22

Verma, Rupesh, Suzita Hirachan, and Yogendra P. Singh. "Palliative Toilet Mastectomy for Advanced Breast Cancer in a University Hospital of Nepal." Journal of Institute of Medicine Nepal 42, no. 1 (2020): 71. http://dx.doi.org/10.3126/jiom.v42i1.37447.

Full text

Abstract:

Introduction In Nepal, half of the breast cancer patients presented in advanced stage III (IIIA 18%, IIIB 22%), and stage IV (10%). Delayed presentations are due to lack of awareness, reluctancy and poor accessibility to health care services often leads to local complications like sloughing of fungating breast lesions, secondary infection and bleeding. The aim of this study was to analyze the advanced breast cancer (ABC) patients who underwent palliative toilet mastectomy. MethodsRetrospective review of all patients presenting with ABC who underwent palliative toilet mastectomy in the br

APA, Harvard, Vancouver, ISO, and other styles

23

Verma, Rupesh, Suzita Hirachan, and Yogendra P. Singh. "Palliative Toilet Mastectomy for Advanced Breast Cancer in a University Hospital of Nepal." Journal of Institute of Medicine Nepal 42, no. 1 (2020): 71. http://dx.doi.org/10.59779/jiomnepal.1091.

Full text

Abstract:

Introduction: In Nepal, half of the breast cancer patients presented in advanced stage III (IIIA 18%, IIIB 22%), and stage IV (10%). Delayed presentations are due to lack of awareness, reluctancy and poor accessibility to health care services often leads to local complications like sloughing of fungating breast lesions, secondary infection and bleeding. The aim of this study was to analyze the advanced breast cancer (ABC) patients who underwent palliative toilet mastectomy. Methods: Retrospective review of all patients presenting with ABC who underwent palliative toilet mastectomy in the breas

APA, Harvard, Vancouver, ISO, and other styles

24

Zerdes, Ioannis, Alexios Matikas, John Lövrot, et al. "PD-1 protein and gene expression in early breast cancer: Prognostic implications." Journal of Clinical Oncology 38, no. 15_suppl (2020): 545. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.545.

Full text

Abstract:

545 Background: We have previously shown the prognostic value of PD-L1 protein and gene expression in early breast cancer (BC), however, the prognostic role of PD-1 expression remains unclear. Methods: The prognostic value of PD-1 in early BC was investigated using three different approaches: i) evaluation of PD-1 at the protein (IHC, immunohistochemistry in tissue microarrays) and mRNA levels in a retrospective patient cohort of 586 patients treated for early BC in Stockholm, Sweden between 1997-2005, ii) systematic review and trial-level meta-analysis of studies published in Medline, Embase,

APA, Harvard, Vancouver, ISO, and other styles

25

Nishiyama, Yasuyuki, Reiki Nishimura, Tomofumi Osako, Yasuhiro Okumura, and Nobuyuki Arima. "Ki-67, p53, and clinical outcomes of patients with triple-negative breast cancer." Journal of Clinical Oncology 30, no. 27_suppl (2012): 142. http://dx.doi.org/10.1200/jco.2012.30.27_suppl.142.

Full text

Abstract:

142 Background: Triple-negative breast cancer (TNBC) tends to produce a poor prognosis because of aggressive tumor biology and lack of targeted agents. Breast cancer with a high Ki-67 value responds better to chemotherapy but is associated with lower relapse-free (RFS) and overall survival rates. The basal-like subtype overlaps with TNBC in approximately 70% to 80% of the cases, and the vast majority of basal-like subtypes have mutated p53. The aim of this study was to evaluate the clinical and prognostic significance of Ki-67 and p53 in patients with TNBC. Methods: We retrospectively reviewed

APA, Harvard, Vancouver, ISO, and other styles

26

Goldstein, Bree G., Hann-Hsiang Chao, Yizeng Yang, Yuliya A. Yermolina, John W. Tobias, and Jonathan P. Katz. "Overexpression of Krüppel-like factor 5 in esophageal epithelia in vivo leads to increased proliferation in basal but not suprabasal cells." American Journal of Physiology-Gastrointestinal and Liver Physiology 292, no. 6 (2007): G1784—G1792. http://dx.doi.org/10.1152/ajpgi.00541.2006.

Full text

Abstract:

Krüppel-like factor 5 ( Klf5; also called IKLF or BTEB2), a zinc-finger transcription factor with proproliferative and transforming properties in vitro, is expressed in proliferating cells of gastrointestinal tract epithelia, including in basal cells of the esophagus. Thus, Klf5 is an excellent candidate to regulate esophageal epithelial proliferation in vivo. Nonetheless, the function of Klf5 in esophageal epithelial homeostasis and tumorigenesis in vivo has not previously been determined. Here, we used the ED- L2 promoter of the Epstein-Barr virus to express Klf5 throughout esophageal epithe

APA, Harvard, Vancouver, ISO, and other styles

27

Liu, Sandy. "CK13 expression in prostate tumors of patients with bone metastases at diagnosis." Journal of Clinical Oncology 34, no. 2_suppl (2016): 257. http://dx.doi.org/10.1200/jco.2016.34.2_suppl.257.

Full text

Abstract:

257 CK13 Expression in Prostate Tumors of Patients with Bone Metastases at Diagnosis Sandy T. Liu, Radu Cadaneanu, Kevin Lai, Bao Zhang, Haibo Liu, Lihong Huo, Colette Galet, William Aronson, Matthew Rettig, Michael Lewis, Isla P. Garraway; University of California Los Angeles, Los Angeles, CA Background: Biomarkers of lethal prostate cancer (PCa) are needed for appropriate clinical management. Benign stem/progenitor (S/P) cells reside in the basal layer of prostatic ducts/acini and function as cells of origin for PCa. Aggressive tumor cells may co-opt properties of S/P cells, such as mechanis

APA, Harvard, Vancouver, ISO, and other styles

28

Rabe, Brian, Anna Lyubetskaya, Andrew Kavran, et al. "Abstract B081: In situ multi-modal characterization of pancreatic ductal adenocarcinoma reveals tumor cell identity as a defining factor of the surrounding microenvironment." Cancer Research 84, no. 17_Supplement_2 (2024): B081. http://dx.doi.org/10.1158/1538-7445.pancreatic24-b081.

Full text

Abstract:

Abstract Pancreatic Ductal Adenocarcinoma (PDAC) is heterogeneous with low tumor purity, prominent microenvironment and complex architecture, which preclude identification of shared tumor intrinsic biology within and across patients. We overcame these challenges by applying complementary spatial omics approaches – providing necessary resolution and context – to primary untreated PDAC tumors from 39 patients capturing 341,949 low-bulk and 531,718 single-cell spatial transcriptomes. Of these, 59,403 low-bulk profiles and 205,665 single-cells represented tumor cells. We leveraged this data to bui

APA, Harvard, Vancouver, ISO, and other styles

29

Rajagopal, Padma, Sonya Reid, Run Fan, et al. "Abstract PO1-15-04: Young Black Women With Triple-Negative Breast Cancer Molecular Subtypes: Population-Specific Patterns and Batch Effect Considerations." Cancer Research 84, no. 9_Supplement (2024): PO1–15–04—PO1–15–04. http://dx.doi.org/10.1158/1538-7445.sabcs23-po1-15-04.

Full text

Abstract:

Abstract Introduction: While triple-negative breast cancer (TNBC) molecular subtypes have been associated with biological differences and clinical outcomes, studies have overwhelmingly been conducted in populations of European or Asian ancestry. Data collected across diverse populations is required to better leverage clinical directions from translational studies in TNBC. Through females recruited through the Black Women: Etiology and Survival of Triple-Negative Breast Cancers (BEST) study, we sought to characterize subtypes and explore associations. Methods: Our study included Black women dia

APA, Harvard, Vancouver, ISO, and other styles

30

Huggins-Puhalla, Shannon Leigh, Jan Hendrik Beumer, Leonard Joseph Appleman, et al. "A phase I study of chronically dosed, single-agent veliparib (ABT-888) in patients (pts) with either BRCA 1/2-mutated cancer (BRCA+), platinum-refractory ovarian cancer, or basal-like breast cancer (BRCA-wt)." Journal of Clinical Oncology 30, no. 15_suppl (2012): 3054. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.3054.

Full text

Abstract:

3054 Background: Veliparib (ABT-888) is an oral, potent inhibitor of PARP 1/2. Preclinically, PARP inhibitors have activity in tumors with defective homologous recombination (HR), particularly those that are BRCA+. Reduced levels of BRCA expression have been observed in ovarian cancer and basal-like breast cancer, which share genotypic and phenotypic similarities with BRCA+ cancers. We postulated that these tumors types may be similarly sensitive to single-agent PARP inhibition. This study sought to establish the maximum tolerated dose (MTD), dose limiting toxicities (DLT), pharmacokinetic and

APA, Harvard, Vancouver, ISO, and other styles

31

Silver, Frederick H., Tanmay Deshmukh, Gayathri Kollipara, and Aanal Patel. "Noninvasive Screening of Basal Cell Carcinomas: A Comparison of the Structure and Physical Properties of Large and Small Nodular Lesions Using Vibrational OCT and Histopathology." Onco 5, no. 2 (2025): 23. https://doi.org/10.3390/onco5020023.

Full text

Abstract:

Background: Approximately 5.4 million nonmelanoma skin cancers are treated each year in the US. Of this number 80 to 90% are basal cell carcinomas. Methods: In this study, we compare optical coherence tomography (OCT) images and vibrational optical coherence tomography (VOCT) measurements made on small and large nodular basal cell carcinomas (BCCs) using histopathology, OCT images, and VOCT physical measurements. OCT images were broken into green, blue, and red subchannel images and compared to histopathology conducted on the excised tissue. Results: While our results suggest that both small a

APA, Harvard, Vancouver, ISO, and other styles

32

Glynn, Sharon A., Dibyangana Bhattacharyya, Shauna Lambe, et al. "Abstract P3-06-05: Human endogenous retrovirus-K (HERV-K) is aberrantly expressed in triple negative breast cancer (TNBC) and associated with increased distant metastasis: Impact of HERV-K knockdown on gene expression patterns and invasive potential of mesenchymal TNBC." Cancer Research 82, no. 4_Supplement (2022): P3–06–05—P3–06–05. http://dx.doi.org/10.1158/1538-7445.sabcs21-p3-06-05.

Full text

Abstract:

Abstract Background: Human endogenous retrovirus K (HERV-K) belongs to a family of endogenous retroviruses that are present in our genome with similarities to present day exogenous retroviruses. HERV-K, like other endogenous retroviruses, is transmitted vertically in a Mendelian fashion through the human genome. This virus can express several proteins but our knowledge of HERV-K expression in human cancers is mainly limited to the envelope (Env) protein. Elevated HERV-K env protein expression has been shown in breast cancer both in in vitro and in vivo studies. Previous work from this laborato

APA, Harvard, Vancouver, ISO, and other styles

33

Rusanen, Peter, Emilia Marttila, Sajeen Bahadur Amatya, et al. "Expression of Toll-like receptors in oral squamous cell carcinoma." PLOS ONE 19, no. 4 (2024): e0300437. http://dx.doi.org/10.1371/journal.pone.0300437.

Full text

Abstract:

Almost 380,000 new cases of oral cancer were reported worldwide in 2020. Oral squamous cell carcinoma (OSCC) accounts for 90% of all types of oral cancers. Emerging studies have shown association of Toll-like receptors (TLRs) in carcinogenesis. The present study aimed to investigate the expression levels and tissue localization of TRL1 to TRL10 and NF-κB between OSCC and healthy oral mucosa, as well as effect of Candida colonization in TRL expression in OSCC. Full thickness biopsies and microbial samples from 30 newly diagnosed primary OSCC patients and 26 health controls were collected. The e

APA, Harvard, Vancouver, ISO, and other styles

34

Barry, Rory, Jennifer Boggs, Máirín McMenamin, and Rupert Barry. "P009 Cylindrocarcinoma: a rare entity." British Journal of Dermatology 191, Supplement_1 (2024): i18—i19. http://dx.doi.org/10.1093/bjd/ljae090.036.

Full text

Abstract:

Abstract A 73-year-old man was referred from a secondary hospital to the dermatology department with a 2-year history of a biopsy-reported recurrent basal cell carcinoma on the left nasal ala. Full-skin examination revealed a solitary 20 × 11-mm, slightly tender, pink-coloured nodule. His past medical history was significant for multiple nonmelanoma skin cancers and colon cancer. No regular medications were prescribed. Mohs micrographic surgery was performed, with two layers required for margin clearance. The Mohs debulk described a carcinoma with features suggestive of a cylindrocarcinoma wit

APA, Harvard, Vancouver, ISO, and other styles

35

Saillard, Charlie, Flore Delecourt, Benoit Schmauch, et al. "Identification of pancreatic adenocarcinoma molecular subtypes on histology slides using deep learning models." Journal of Clinical Oncology 39, no. 15_suppl (2021): 4141. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.4141.

Full text

Abstract:

4141 Background: Pancreatic adenocarcinoma (PAC) is predicted to be the second cause of death by cancer in 2030 and its prognosis has seen little improvement in the last decades. PAC is a very heterogeneous tumor with preeminent stroma and multiple histological aspects. Omic studies confirmed its molecular heterogeneity, possibly one of the main factors explaining the failure of most clinical trials. Two and three transcriptomic subtypes of tumor cells and stroma respectively, were described with major prognostic and predictive implications. The tumor subtypes, Basal-like and Classical, have b

APA, Harvard, Vancouver, ISO, and other styles

36

Gaspar, Catia Fava, Grégoire Marret, Benson Z. Wu, et al. "Integrative analysis of tumor microenvironment in advanced pancreatic cancer: Unraveling genomic and immune landscape for targeted therapies." Journal of Clinical Oncology 43, no. 16_suppl (2025): 4182. https://doi.org/10.1200/jco.2025.43.16_suppl.4182.

Full text

Abstract:

4182 Background: An understanding of genotype and immunophenotype interactions in advanced pancreatic ductal adenocarcinoma (PDAC) is important in designing combination strategies. In addition, PDAC subtypes may harbor unique tumor immune microenvironments (TMEs) and confer differential sensitivity to KRAS inhibitors (KRASi). We aimed to characterize the baseline TME in advanced PDAC and its relationship with genomic, transcriptomic and clinical data. Methods: The COMPASS trial (NCT02750657) investigated whole genome (WGS) and transcriptome (RNA-Seq) sequencing in patients (pts) receiving firs

APA, Harvard, Vancouver, ISO, and other styles

37

Jones, H. E., L. Goddard, J. M. W. Gee, et al. "Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells." Endocrine-Related Cancer 11, no. 4 (2004): 793–814. http://dx.doi.org/10.1677/erc.1.00799.

Full text

Abstract:

De novo and acquired resistance to the anti-tumour drug gefitinib (ZD1839; Iressa), a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) has been reported. We have determined whether signalling through the IGF-I receptor (IGF-1R) pathway plays a role in the gefitinib-acquired resistance phenotype. Continuous exposure of EGFR-positive MCF-7-derived tamoxifen resistant breast cancer cells (TAM-R) to 1 μM gefitinib resulted in a sustained growth inhibition (90%) for 4 months before the surviving cells resumed proliferation. A stable gefitinib-resistant subline (TAM/T

APA, Harvard, Vancouver, ISO, and other styles

38

Iwase, H., Y. Yamamoto, J. Kurebayashi, et al. "Clinicopathologic and prognostic features of triple-negative breast cancer analyzed in registration data of the Japanese Breast Cancer Society, 11705 cases." Journal of Clinical Oncology 27, no. 15_suppl (2009): e22122-e22122. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.e22122.

Full text

Abstract:

e22122 Background: Triple-negative (TN) breast cancers which are negative for ER, PgR, and HER2 by immunohistochemistry are associated with a poor prognosis. To clarify the characteristics of TN tumors, the data of the registration committee of the Japanese Breast Cancer Society were analyzed with respect to clinicopathologic factors, response to neoadjuvant chemotherapy (NAC) and prognosis. Methods: Of 14,748 cases that were registered in 2004, 11,705 cases (79.4%) were examined for ER, PgR, and HER2 status, which was based on local institute. In the 2,331 cases of all registered cases, the p

APA, Harvard, Vancouver, ISO, and other styles

39

Al-Zahrani, Khalid N., Ellen R. Langille, Andreea Obersterescu, et al. "Abstract A022: Decoding aneuploidy: Identifying drivers and therapeutic targets in recurrent breast cancer copy number alterations." Cancer Research 85, no. 5_Supplement (2025): A022. https://doi.org/10.1158/1538-7445.genfunc25-a022.

Full text

Abstract:

Abstract Chromosome instability is highly prevalent in cancer and drives large scale chromosomal imbalances, known as aneuploidies. However, how aneuploidy contributes to tumorigenesis remains difficult to study due to the vast numbers of genes affected. To address these limitations, we have developed a CRISPR-Knock Out and Activation Linked Assay (CRISPR-KOALA), which enables systematic high-throughput bidirectional genetic screens in immune-competent mouse models of cancer. Using CRISPR-KOALA we screened the mouse orthologs of all 3,752 genes residing on the ten most frequently altered human

APA, Harvard, Vancouver, ISO, and other styles

40

Vaklavas, Christos, Vandana Gupta Abramson, Nancy U. Lin, et al. "TBCRC 019: An open label, randomized, phase II trial of nanoparticle albumin-bound paclitaxel (nab-PAC) with or without the anti-death receptor 5 (DR5) monoclonal antibody tigatuzumab (TIG) in patients with metastatic triple negative breast cancer (TNBC)." Journal of Clinical Oncology 31, no. 15_suppl (2013): 1052. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.1052.

Full text

Abstract:

1052 Background: TIG, an agonistic anti-DR5 monoclonal antibody, triggers apoptosis in DR5+ human tumor cells without the aid of crosslinking. TIG has shown strong in vitro and in vivo activity against basal-like breast cancer cells that is enhanced by chemotherapy like paclitaxel. Methods: Randomized 2:1 phase II trial of nab-PAC with/without TIG in TNBC patients. Patients stratified by prior exposure to chemotherapy in the metastatic setting. Patients received nab-PAC weekly x 3 and TIG every other week, every 28 days. Primary endpoint was overall response rate (ORR). Secondary objectives we

APA, Harvard, Vancouver, ISO, and other styles

41

Gamal, Sameh, Nefertiti A. El-Nikhely, Hesham Nematallah, and Hesham M. Saeed. "Abstract 4317: The role of autophagy in triple negative breast cancer." Cancer Research 84, no. 6_Supplement (2024): 4317. http://dx.doi.org/10.1158/1538-7445.am2024-4317.

Full text

Abstract:

Abstract Breast cancer (BC) remains a global health concern, being the most common cancer amongst women in the world, and the second-leading cause of cancer related death. Triple-negative breast cancer (TNBC) represents a challenging frontier in oncology, characterized by its aggressiveness and its unique molecular profile devoid of the known receptors. Its elusiveness lies in the inherent heterogeneity within its subtypes, contributing to diverse clinical behaviours and treatment responses. TNBC has also shown elevated basal autophagy level as a pro-survival mechanism to make up for the incre

APA, Harvard, Vancouver, ISO, and other styles

42

Turner, Nicholas, Jorge Reis-Filho, Matthew Goetz, et al. "Abstract GS03-06: Genomic and transcriptomic profiling of primary tumors from patients with HR+, HER2-, node-positive, high-risk early breast cancer in the monarchE trial." Cancer Research 84, no. 9_Supplement (2024): GS03–06—GS03–06. http://dx.doi.org/10.1158/1538-7445.sabcs23-gs03-06.

Full text

Abstract:

Abstract Background Two years of adjuvant abemaciclib combined with endocrine therapy (ET) resulted in significant and clinically meaningful improvement in invasive disease-free survival (IDFS) and distant relapse-free survival (DRFS) in patients (pts) with HR+, HER2-, node-positive, high-risk early breast cancer in the monarchE trial (NCT03155997). Abemaciclib benefit was sustained beyond the completion of treatment (tx) with deepening magnitude of absolute benefit in IDFS and DRFS at 5 years. Here, we evaluate comprehensive molecular profiling of archived primary tumor tissue and association

APA, Harvard, Vancouver, ISO, and other styles

43

Bellmunt, Joaquim. "Stem-Like Signature Predicting Disease Progression in Early Stage Bladder Cancer. The Role of E2F3 and SOX4." Biomedicines 6, no. 3 (2018): 85. http://dx.doi.org/10.3390/biomedicines6030085.

Full text

Abstract:

The rapid development of the cancer stem cells (CSC) field, together with powerful genome-wide screening techniques, have provided the basis for the development of future alternative and reliable therapies aimed at targeting tumor-initiating cell populations. Urothelial bladder cancer stem cells (BCSCs) that were identified for the first time in 2009 are heterogenous and originate from multiple cell types; including urothelial stem cells and differentiated cell types—basal, intermediate stratum and umbrella cells Some studies hypothesize that BCSCs do not necessarily arise from normal stem cel

APA, Harvard, Vancouver, ISO, and other styles

44

Reyes, Giovanna Merchand, Ramasamy Santhanam, Frank H. Robledo Avila, et al. "Abstract LB050: Targeting cells in the microenvironment as a novel therapeutic strategy for chronic lymphocytic leukemia." Cancer Research 82, no. 12_Supplement (2022): LB050. http://dx.doi.org/10.1158/1538-7445.am2022-lb050.

Full text

Abstract:

Abstract Chronic lymphocytic leukemia (CLL) is a disease that affects the elderly, characterized by the accumulation of mature B cells in the bloodstream. With an estimation incidence of 21,250 new cases diagnosed and 4,320 deaths for 2021, CLL is still considered a non-curable disease despite the wide therapeutic alternatives. CLL, like other malignant diseases, involves the activity of different cells in the microenvironment that support the leukemic cells by providing survival signals, even in presence of therapeutic agents. Among these cells, nurse-like cells (NLC) are of great importance.

APA, Harvard, Vancouver, ISO, and other styles

45

Ciruelos, Eva, Tomás Pascual, Mafalda Oliveira, et al. "Abstract PD8-03: Palbociclib and trastuzumab for HER2-positive metastatic breast cancer (SOLTI-1303 PATRICIA): Final results from cohort A and B, prospective, open-label, multicenter phase II study." Cancer Research 82, no. 4_Supplement (2022): PD8–03—PD8–03. http://dx.doi.org/10.1158/1538-7445.sabcs21-pd8-03.

Full text

Abstract:

Abstract Background: CDK4/6 inhibition combined with anti-HER2 therapy is currently being explored in HER2-positive (HER2+) breast cancer (BC). Here, we report the final efficacy and genomic analysis of cohort A and B of the PATRICIA phase II trial evaluating palbociclib in combination with trastuzumab in advanced HER2+ BC. Methods: PATRICIA is a prospective, open-label, multicenter phase II trial. Patients had received 2-4 prior lines of anti-HER2-based regimens. Treatment consisted of palbociclib 200 mg daily for 2 weeks and 1 week off plus trastuzumab. The study was based on a Simon two-sta

APA, Harvard, Vancouver, ISO, and other styles

46

Basho, Reva K., Clinton Yam, Jason B. White, et al. "Incidence of PI3K pathway alteration and response to neoadjuvant therapy (NAT) in triple negative breast cancer (TNBC) subtypes." Journal of Clinical Oncology 38, no. 15_suppl (2020): 561. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.561.

Full text

Abstract:

561 Background: Limited cell line and human data suggest that TNBCs characterized as mesenchymal and luminal androgen receptor (LAR) commonly have alterations in the PI3K pathway. More data is needed to better characterize the role of the PI3K pathway across TNBC subtypes. Methods: Pre-treatment tumor biopsies were collected from operable TNBC patients (pts) enrolled on a clinical trial of genomically tailored NAT (ARTEMIS; NCT02276443). Tumors were categorized into 5 groups using the Pietenpol criteria: basal-like (BL) comprised of BL-1 and BL-2, mesenchymal and mesenchymal stem-like (M), imm

APA, Harvard, Vancouver, ISO, and other styles

47

Johnson, Gary L., Keith D. Amos, James S. Duncan, et al. "Kinome reprogramming response to MEK inhibition: A window-of-opportunity trial in triple-negative breast cancer (TNBC)." Journal of Clinical Oncology 31, no. 15_suppl (2013): 512. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.512.

Full text

Abstract:

512 Background: Targeted therapy (Rx) in TNBC is challenging due to heterogeneity and cancer cell kinome “reprogramming” in response to targeted kinase inhibitors (Cell 149:307, 2012). In preclinical TNBC models specific kinases (e.g., DDR1/2, PDGFRbeta, VEGFR2, AXL) are activated in response to MEK inhibition. Our studies define unique kinome reprogramming in basal-like (BBC) versus claudin-low (CL). This study compared kinome profiles of TNBC pre- and post- MEK1/2 inhibition with GSK1120212 (trametinib, T) using multiplexed inhibitor beads coupled with mass spectrometry (MIB/MS). Methods: El

APA, Harvard, Vancouver, ISO, and other styles

48

Bedi, Deepa, Rachel Martini, Melissa B. Davis, and Clayton Yates. "Abstract B101: Obesity mediates altered triple-negative breast cancer tumor biology in African American women independent of ancestry." Cancer Epidemiology, Biomarkers & Prevention 32, no. 12_Supplement (2023): B101. http://dx.doi.org/10.1158/1538-7755.disp23-b101.

Full text

Abstract:

Abstract African American (AA) breast cancer (BC) is associated with a higher incidence of aggressive BC phenotypes at younger age, higher grade of tumor as compared to BCs of age-matched patients of European American (EA). For AA women, there is a higher frequency of the more aggressive TNBC subtype and of the PAM50-molecular basal subtype. AA tumors are enriched for inflammatory and immune pathways, implicating inherited susceptibility associated with African ancestry. Obesity induces a state of low-grade inflammation. AA women tend to be more obese than EA and have elevated a inflammatory m

APA, Harvard, Vancouver, ISO, and other styles

49

Sousa, Elisa Rodrigues, Eugenio Zoni, Mario Scarpa, et al. "Abstract 22: A new transgenic mouse model to explore the role of Cripto signaling in lethal prostate cancer." Cancer Research 83, no. 7_Supplement (2023): 22. http://dx.doi.org/10.1158/1538-7445.am2023-22.

Full text

Abstract:

Abstract Introduction: Prostate cancer (PCa) at its early stages is treated with surgery or androgen-deprivation therapy, but PCa can turn castration resistant possibly due to pre-existing stem cell-like cells that reinitiate tumor growth and lead to metastasis. Given that human tumors express high levels of the oncofetal Cripto, our hypothesis is that Cripto might play a role in PCa initiation and progression, so we conditionally knock out Cripto in GEMMs models representative of early and late metastatic PCa to study its oncogenic potential. Methods: Conditional Cripto knock out (CRIPTOflox/

APA, Harvard, Vancouver, ISO, and other styles

50

Sousa, Elisa Rodrigues, Eugenio Zoni, Mario Scarpa, et al. "Abstract A044: Generation of a new mouse model to study the role of oncofetal Cripto in aggressive lethal prostate cancer." Cancer Research 83, no. 11_Supplement (2023): A044. http://dx.doi.org/10.1158/1538-7445.prca2023-a044.

Full text

Abstract:

Abstract Introduction: Early stages of prostate cancer (PCa) are commonly treated with surgery and androgen-deprivation therapy, but PCa can turn castration resistant due to pre-existing stem cell-like cells which might re-initiate tumor growth and lead to metastasis. Previously, it has been shown that human tumors express high levels of Cripto, an oncofetal protein, for this reason our hypothesis is that Cripto might play a role in PCa initiation and progression. We aim to study its oncogenic features in GEMMs models that are representative of early and late metastatic PCa. Methods: We perfor

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!